Derma Sciences and Comvita to Move Forward with MEDIHONEY(TM) Product Line.

Companies eager to leverage global success and clinical evidence base

PRINCETON, N.J. -- Derma Sciences, Inc. (OTCBB: DSCI), a manufacturer and marketer of advanced wound care products, today announced that it and its partner, Comvita New Zealand, Ltd, are changing the brand name of their honey-based product line to MEDIHONEY(TM), effective immediately. Previously, both companies had intended to market the products under the API-MED(TM) brand. The MEDIHONEY(TM) brand is an asset Comvita acquired through its recent purchase of Medihoney-Pty Ltd., formerly a subsidiary of the Australian-based Capilano group. MEDIHONEY(TM) is the market-leading line of Active Leptospermum honey-based wound and burn dressings, and is currently sold throughout Europe, Australia, and New Zealand. The brand has been featured in multiple peer-reviewed journal articles on the use of honey for the management of wounds and burns, with several additional articles set to be published in the fall of 2007.

Ed Quilty, CEO of Derma Sciences, said "This is an important step in the development of our Active Manuka (Leptospermum)-based product line. The clinical staff running the MEDIHONEY(TM) brand has done an excellent job facilitating the creation of a solid base of evidence, including randomized controlled trials that have been published in multiple peer-reviewed journals. Additionally, their expansive ongoing clinical development program will be a huge asset as we move forward with the commercialization of our products. Lastly, as we consider our strategy for filing an IND in the US for our product as a drug, the MEDIHONEY(TM) patented formulation will provide a good level of protection of this asset moving forward."

Brett Hewlett, CEO of Comvita, added "Leveraging the MEDIHONEY(TM) brand is a key reason for our acquisition of the company. We now have a full library of clinical evidence supporting the use of some of our key products, and a great foundation of clinical activity currently underway upon which to build."

The MEDIHONEY(TM) brand currently consists of several products, including wound care and skin care formulations. These will be added to the Derma Sciences / Comvita line, which consists of multiple wound and burn care dressing configurations. The first of these dressings, a calcium alginate dressing with Active Manuka (Leptospermum) Honey was cleared for use by Health Canada in June and then by the FDA in July. It is the first honey-based product cleared for use in the management of wounds and burns in North America. The product, as well as Derma Sciences and Comvita, were featured in an August 7 article in The Washington Post on the use of Active Manuka (Leptospermum) Honey in the management of wounds and burns.

For more information and to see a list of MEDIHONEY(TM) peer-reviewed articles, please go to www.dermasciences.com.

About Derma Sciences:

Derma Sciences is a manufacturer and marketer of advanced wound care products, with operations based in the US and Canada, and sales worldwide. The company sources Active Manuka (Leptospermum) Honey from Comvita New Zealand, Ltd. Comvita controls over 70% of the flow of manuka honey, and owns several patents around the use of honey in wound dressings. In February 2006, Derma Sciences and Comvita entered into a licensing agreement granting Derma Sciences the exclusive rights to Comvita's technology and honey for marketing and sale to healthcare professionals into the North, South, and Central American markets. Derma Sciences is also the global manufacturer for the Comvita brand of several of the honey-based dressings. Comvita owns 14% of Derma Sciences stock (10% fully diluted), DSCI.OB, and recently purchased its largest competitor in honey-based dressings, Medihoney-Pty, Ltd.